Product Description
Off-the-shelf gamm delta T cells with a CD19-redirected Chimeric Antigen Receptor. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT06092047)
Mechanisms of Action: CAR-T, CD19
Novel Mechanism: No
Modality: Allogeneic CAR-T
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: PersonGen BioTherapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers|Oncology Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06092047 |
PG-CART-UTAA09-001 | P1 |
Recruiting |
Healthy Volunteers|Oncology Unspecified |
2026-07-01 |
50% |
2025-05-17 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|